Pharma Industry News Update: 22 November 2016
Featured Conference 
Social Media in the Pharmaceutical Industry 18 – 19 January 2017 | London, UK
SMi Group’s sell-out series Social Media in the Pharmaceutical Industry returns to London on the 18th and 19th of January 2017, providing the perfect platform to explore the latest trends and technology in e-healthcare to help you develop a robust digital strategy. This year’s agenda features key opinion leaders and pharma companies at the cutting edge of social media innovation including CREATION, MHRA, MSD, Lundbeck, Pfizer, AbbVie, GE Healthcare, and more. More…
How is Pharma Using Social Media?
Over the past decade, the rise of social media has caused a huge shift in the way businesses interact with customers. Pharma, often thought of as a guarded industry when it comes to social, is upping its game and using social to reach a wide audience including patients and healthcare professionals.
More here.
Related articles:
Pfizer Offers $250,000 in Prize Funding for Metastatic Breast Cancer Disruptive Technology!
Pfizer asks: Can you develop disruptive, technology-enabled solutions to help enrich the lives of patients living with mBC?
Pfizer Oncology has partnered with Health 2.0 to bring you the Advancing Care for Patients Living with mBC Challenge. This global technology challenge seeks to close the gaps in mBC care and catalyze the development of meaningful solutions to support mBC patients along the care continuum and improve their overall quality of life.
The challenge is organized into 3 phases with goals that correlate to successive stages in technology development.
More here…
Related articles:
- Johnson & Johnson Expands Its Membership in the Digital Innovation Club
- MSD UK Joins #Pharma Digital Accelerator Club
- Takeda Joins #Pharma Digital Accelerator Club
The Dark Web & Illegal Drugs
Imagine that the whole internet is a forest – a vast expanse of luscious green as far as the eye can see. And in the forest are well worn paths – to get from A to B. Think of these paths as popular search engines – like Google – allowing you as the user the option to essentially see the wood from the trees and be connected. But away from these paths – and away from Google – the trees of the forest mask your vision.
Just like the forest, the dark web hides things well – it hides actions and it hides identities. The dark web also prevents people from knowing who you are, what you are doing and where you are doing it. It is not surprising, then, that the dark web is often used for illegal activity and that it is hard to police.
More here…
Related article:
Consumers On Their Own When It Comes to Protecting Themselves Against Security Threats to Their Wearable Devices
As the healthcare industry continues to embrace the Internet of Things, cybersecurity may present unprecedented health and privacy risks to patients. Wireless-enabled medical devices are increasingly common. For some patients, this means that their hearts are, quite literally, connected to the Internet of Things. For others, mobile medical apps and wearable products are collecting personal health data that may be inadequately protected.
The medical device industry came under fire this year when a Senator from California sent a letter to the top five U.S. medical device manufacturers expressing “serious concerns that the cybersecurity vulnerabilities in medical devices are putting the health and safety of patients in California and across the country at risk.”
“But what about my fitness tracker?” you may ask. The explosive growth of wearable wellness products and mobile medical apps has created another avenue for cyber-threats.
More here…
Related articles:
- Infographic: 2016 State of Mobile Health App Security
- FDA’s Cybersecurity Draft Guidance for Medical Devices
- FDA’s Draft Medical Device Cybersecurity Guidelines Lack Teeth, Say Experts
- FBI Warns About IoT Security Vulnerability, But What to Do About It?
Featured Survey 
Direct-to-Consumer Off-Label Drug Promotion SurveyThis survey solicits your opinion possible FDA future decisions regarding off-label drug promotion to patient and consumer audiences. CLICK HERE to take the survey.
